Healix

Ceftolozane/Tazobactam: Outpatient Treatment of Gram-Negative Infections at Physician Office Infusion Centers (POICs)

Authors:
Ramesh V. Nathan, MD, FIDSA – Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA
Fernando S. Alvarado, MD, FACP, MPH, TM – Infectious Disease Consultants, Altamonte Springs, FL
Richard C. Prokesch, MD, FACP, FIDSA – Infectious Diseases Associates, Riverdale, GA
Quyen Luu, MD – Quyen Luu, MD, Macon, GA;
Thomas K. Sleweon, MD – ID Specialists of Indiana, Highland, IN 
Claudia P. Schroeder, PharmD, PhD – Healix Infusion Therapy, Inc., Sugar Land, TX
Lucinda J. Van Anglen, PharmD – Healix Infusion Therapy, Inc., Sugar Land, TX

View Poster View Abstract

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.

FacebookTwitterLinkedInarrow1arcsearchiconowdtnotfound